Slide 1: Half Year 2021 Financial Reporting
Financial Reporting 20 HALF YEAR 21
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: CEO quote: Building momentum towards a fully-fledged biopharmaceutical company
“Building momentum towards becoming a fully-fledged biopharmaceutical company.” Jean-Paul Clozel Chief Executive Officer 3 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 4: Highlights HY 2021
Daridorexant NDA / Highlights MAA submitted to US FDA, EMA, Swissmedic Phase 3 studies HY Ponesimod approved with lucerastat and aprocitentan 21 in the US and EU fully recruited Clazosentan NDA Phase 2b study with submitted to PMDA cenerimod recruitment Phase 3 study with concluded selatogrel initia
Slide 5: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Build a world-class commercial organization achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Deliver at least three products to market 4 Fuel our pipeline with new discoveries 5 Utilize state-of-the-art technologies t
Slide 6: Deliver at least three products to market
Deliver at least three products to market Compound Mechanism of Action Target Indication Daridorexant Dual orexin receptor antagonist Insomnia Aprocitentan* Dual endothelin receptor antagonist Resistant hypertension management Vasospasm associated with aneurysmal Clazosentan Endothelin receptor anta
Slide 7: Daridorexant for insomnia
Daridorexant for insomnia Dual orexin receptor antagonist First sleeping pill to show a consistent benefit in daytime functioning, using a validated instrument • Daridorexant Phase 3 program has concluded – supporting the chronic use of daridorexant in insomnia • New drug application (NDA) submitted
Slide 8: SOS-AMI – Phase 3 registration study
SOS-AMI – Phase 3 registration study Concept Patient Onset of Patient recognizes first self-injects the Diagnosis symptoms symptoms study drug and calls emergency Selatogrel is investigational, in development and not approved or marketed in any country. 8 Half Year 2021 Financial Reporting | 27 Jul
Slide 9: Build a world-class commercial organization
Build a world-class commercial organization Prioritization Commercial affiliates • US + EUCAN region established daridorexant • US: Radnor • Japan • France: Paris clazosentan • Germany: Munich • Italy: Milan • Spain: Madrid …staffed by top • UK: London tier talent • Japan: Tokyo 9 Half Year 2021 Fin
Slide 10: Utilize state-of-the-art technologies to drive innovation
Utilize state-of-the-art technologies to drive innovation … from bench to bedside 10 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 11: Fuel our pipeline with new discoveries
Fuel our pipeline with new discoveries Single-center approach Few platforms of expertise Fully integrated research informatics Multiple therapeutic areas Focus on High medical input small molecules 11 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 12: Bring Idorsia to sustainable profitability
Bring Idorsia to sustainable profitability Rich pipeline allows substantial leverage of the commercial organization Net sales • Primary Care: daridorexant Milestones & • Orphan: lucerastat, Royalty streams clazosentan • ponesimod • Specialty: cenerimod, • aprocitentan selatogrel • T-type calcium cha
Slide 13: CFO quote: Preparations for first product launches
“Preparations for our first product launches in three regions are well underway.” André C. Muller Chief Financial Officer 13 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 14: US GAAP net results
US GAAP net results 20 HALF YEAR in CHF millions, rounding differences may occur 21 Non-GAAP US GAAP Financial results as of June 30, 2021 14 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 15: Non-GAAP operating expenses
Non-GAAP operating expenses 20 HALF YEAR in CHF millions, rounding differences may occur 21 -49 -54 -9 -5 -4 -6 -97 -115 -34 -68 -193 -248 6M 2020 6M 2021 Research Development Milestones Inventory build SG&A Non-GAAP operating expenses Financial results as of June 30, 2021 15 Half Year 2021 Financia
Slide 16: Cash flow
Cash flow 20 HALF YEAR in CHF millions, rounding differences may occur 21 Financial results as of June 30, 2021 16 Half Year 2021 Financial Reporting | 27 Jul 2021
Slide 17: Liquidity
Liquidity 20 HALF YEAR in CHF millions, rounding differences may occur 21 1,200 192 927 927 9 237 Cash deposits Other FX > 12 months 867 763 Cash deposits USD < 12 months 681 Cash and CHF Cash equivalents 141 164 Liquidity @ Liquidity @ Liquidity @ Dec 31, 2020 Jun 30, 2021 Jun 30, 2021 Financial re
Slide 18: Financial Guidance for 2021
Financial Guidance for 2021 • Functional R&D expenses • Non-GAAP OPEX around CHF 360 million • Depreciation & Amortization • Functional SG&A ~ CHF 20 million around CHF 220 million • Stock-Based Compensation • Inventory build ~ CHF 25 million around CHF 35 million • Milestone payment CHF 5 million N
Slide 19: Idorsia is at an inflection point with major near-term catalysts
Idorsia is at an inflection point with major catalysts expected in the near-term 2021 2022 1H 1H mid- 2H Clazosentan 1H 1H mid- 2H 2H Aprocitentan RESULTS : Phase 3 Clazosentan RESULTS : Phase 3 “REACT” Daridorexant APPROVAL & “PRECISION” Cenerimod commercial Lucerastat APPROVAL & Selatogrel RESULTS
Slide 20: Road to becoming a leading biopharma company
Road to becoming a leading biopharma company Profitability on the mid-term Leveraging our global horizon infrastructure in the long-term • Ponesimod revenue sharing • Lucerastat, clazosentan (outside of Japan)… • Daridorexant in US & EUCAN • Aprocitentan with J&J • Clazosentan in Japan • …cenerimod
Slide 21: CEO quote: Building momentum towards a fully-fledged biopharmaceutical company
“Building momentum towards becoming a fully-fledged biopharmaceutical company.” Jean-Paul Clozel Chief Executive Officer 21 Half Year 2021 Financial Reporting | 27 Jul 2021